Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Anti GD2 chimeric antigen receptor T cell therapy Bellicum Pharmaceuticals (Primary) ; Cyclophosphamide; Fludarabine; Pembrolizumab; Rimiducid
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms GRAIN
- 26 Dec 2015 Planned End Date changed from 1 Nov 2030 to 1 Oct 2030, according to ClinicalTrials.gov record.
- 26 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
- 30 Oct 2015 Planned End Date changed from 1 Aug 2030 to 1 Nov 2030 as reported by ClinicalTrials.gov record.